Drug Discovery Featured Articles & Applications

91. Navigating The Murky Waters Of Patent Claims Involving AI After Amgen v. Sanofi 8/24/2023

    In May 2023, the Supreme Court issued a ruling on the Section 112 enablement requirement for patents in Amgen v. Sanofi. What does this mean for patent claims involving artificial intelligence (AI) going forward? These Haynes Boone attorneys explain.

92. 4 Ways Academic Medical Centers Can Capture Greater Value In The Cell & Gene Therapy Industry 8/22/2023

    Academic medical centers (AMCs) are unique in the way academic functions and healthcare delivery services are co-located. With strong research capabilities, access to leading scientists, access to patients, and more, AMCs are uniquely positioned to conduct research and clinical trials, enable process development and manufacturing, and more.

93. Are KRAS Inhibitors Poised To Cure Cancer? 8/21/2023

    The KRAS gene, a crucial component of cell signaling pathways involved in cell growth and division, is frequently mutated in various cancers. By targeting the gene, KRAS inhibitors aim to block the aberrant signaling that promotes cancer cell proliferation. Amgen's sotorasib became the first approved KRAS inhibitor, opening up an exciting field.

94. From Chips To Genes: The New Era Of Animal Models Transforming Drug Testing And Research 8/16/2023

    The U.S. is at the forefront of the AI-based research trend surge to elevate the understanding of human physiology, testing potential therapies, and identifying disease mechanisms. Let's examine the five most promising innovative advancements in animal models, as well as key considerations for those working in the field.

95. The Critical Role Of Medical Affairs In Discovery Through Phase 2 Clinical Trials 8/14/2023

    When is the right time to engage medical affairs? If you're not sure when MA should make its debut, consider these 11 unique medical affairs contributions that should begin in discovery, be directly connected to other cross-functional deliverables, and continue through launch to support a successful R&D program.

96. Navigating Expanded Access For Experimental Cell & Gene Therapies 8/9/2023

    With the hype of cell and gene therapies' potential, more and more patients have become interested in non-trial access to experimental therapies that haven't yet been approved. One mechanism is the FDA’s expanded access pathway. This article shares the International Society for Cell & Gene Therapy's three areas of concern and recommendations for developers.

97. The ADC Market To Triple By 2030, Driven By Big Pharma Developments 8/8/2023

    After two decades of trial and error in antibody–drug conjugates (ADC) development, the field is poised to deliver a plethora of targeted drugs to treat a wide range of tumor types. Let's take a look at new market research and some notable recent developments in the space.

98. The Current & Future Outlook For Precision Medicine In Women's Health 8/7/2023

    The promise of shifting away from a “one size fits all” strategy in women’s health is most clear in advances in breast cancer care, but more recent activity shows precision medicine is possible across many aspects of women’s health outside oncology.

99. 4 Tips To Leverage Your Ingredient Supplier For Faster Formulation 8/3/2023

    Speed to formulation plays a critical role in recouping the investment for a new drug. Many ingredient suppliers have an experienced analytical group and material scientist group, and drug developers should reach out and leverage that expertise with these four strategies.

100. Strategic Business Pivoting For Cell & Gene Therapy Startups 8/1/2023

     Cell and gene therapy companies need to implement a strategy that helps build a pipeline more quickly and effectively. Let's examine lean startup culture, identifying the signs that your company may need to pivot, and the four primary pivots for more nimble success.